> Detailanzeige

Rau, Cornelius; Auer-Hackenberg, Lorenz; Deubzer, Hedwig E.; Schwabel, Elisabeth; Jaros, Maria; Diederichs, Antonia; Lehrnbecher, Thomas; Holm, Mette; von Linstow, Marie-Louise; Martin, Luise; Dinges, Sarah Svenja; Rothensteiner, Maria; Siepermann, Meinolf; Strenger, Volker; von Both, Ulrich; Teig, Norbert; Brinkmann, Folke; Leeb, Franziska; Zeitlinger, Markus; Kobbe, Robin; Götzinger, Florian

Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series
  • Beteiligte: Rau, Cornelius; Auer-Hackenberg, Lorenz; Deubzer, Hedwig E.; Schwabel, Elisabeth; Jaros, Maria; Diederichs, Antonia; Lehrnbecher, Thomas; Holm, Mette; von Linstow, Marie-Louise; Martin, Luise; Dinges, Sarah Svenja; Rothensteiner, Maria; Siepermann, Meinolf; Strenger, Volker; von Both, Ulrich; Teig, Norbert; Brinkmann, Folke; Leeb, Franziska; Zeitlinger, Markus; Kobbe, Robin; Götzinger, Florian
  • Erschienen: Ovid Technologies (Wolters Kluwer Health), 2023
  • Erschienen in: Pediatric Infectious Disease Journal
  • Sprache: Englisch
  • DOI: 10.1097/inf.0000000000003773
  • ISSN: 0891-3668
  • Schlagwörter: Infectious Diseases ; Microbiology (medical) ; Pediatrics, Perinatology and Child Health
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec> <jats:title>Background:</jats:title> <jats:p>Although severe COVID-19 in children is rare, those with certain pre-existing health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are potent antiviral agents that reduce adverse clinical outcomes in adults, but are commonly not approved for use in pediatric patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>We retrospectively evaluated mAb treatment in children &lt;12 years of age or &lt;40kg with SARS-CoV-2 infection between January 1, 2021, and March 7, 2022, in 12 tertiary care centers in 3 European countries.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>We received data from 53 patients from Austria, Denmark and Germany. Median age was 5.4 years [0–13.8, interquartile range (IQR) = 6.2], and median body weight was 20 kg (3–50.1, IQR = 13). The most frequent SARS-CoV-2 variant in this study, if known, was Omicron, followed by Delta and Alpha. Pre-existing conditions included immunodeficiency, malignancy, hematologic disease, cardiac disease, chronic lung disease, chronic liver disease, kidney disease and diabetes. Forty-two patients received sotrovimab (79%), 9 casirivimab/imdevimab (17%) and 2 bamlanivimab (4%). All but 1 patient survived. Median duration of hospital stay was 3 days (0–56, IQR = 6). Seven patients required treatment in an intensive care unit, and 5 required high-flow nasal cannula treatment. Potential side effects included neutropenia (6/53, 11%), lymphopenia (3/53, 6%), nausea or vomiting (2/53, 4%), rise of alanine transaminase (1/53, 2%) and hypotonia (1/53, 2%).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>MAb treatment was well tolerated by children in this cohort.</jats:p> </jats:sec>